Liver Cancer Treatment Market to Reach $12.88 Billion by 2033, Driven by 11.4% CAGR - Leading Companies are Eli Lilly and Company, AstraZeneca, Eisai Inc.

Liver Cancer Treatment Market size reached US$ 4.58 billion in 2024 and is expected to reach US$ 12.88 billion by 2033, growing at a CAGR of 11.4% during the forecast period 2025-2033

According to DataM Intelligence has published a new research report on "Liver Cancer Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

📌 Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/liver-cancer-treatment-market?rk

➣ Recent Developments:

United States: Recent Industry Developments - Liver Cancer Treatment
✅ July 2025 - Bristol Myers Squibb reported positive Phase III results for its nivolumab + cabozantinib combination therapy in advanced hepatocellular carcinoma (HCC). The regimen demonstrated improved overall survival and reduced disease progression rates.

✅ June 2025 - Merck (MSD) expanded access to Keytruda for first-line HCC treatment after receiving FDA supplemental approval. The expansion supports broader immunotherapy adoption for high-risk patient groups.

✅ May 2025 - Hepion Pharmaceuticals advanced its oral therapy rencofilstat into late-stage trials targeting liver fibrosis-driven HCC. The drug is the first in its class focusing on cyclophilin modulation to prevent tumor progression.

Europe: Recent Industry Developments - Liver Cancer Treatment
✅ August 2025 - Germany: Bayer AG initiated a new clinical trial evaluating Stivarga (regorafenib) in combination with a next-generation immune checkpoint inhibitor for advanced HCC. The study aims to improve survival outcomes in second-line treatment settings.

✅ July 2025 - United Kingdom: AstraZeneca reported strong early-stage results for its IL-2 pathway agonist combined with durvalumab in liver cancer. The combination showed enhanced immune activation and tumor shrinkage in difficult-to-treat HCC patients.

✅ June 2025 - France: Institut Gustave Roussy launched Europe's first multi-center study using personalized neoantigen vaccines for hepatocellular carcinoma. The initiative aims to develop custom tumor-specific vaccines to reduce recurrence after surgery or ablation.

➣ Top Industry Players:

Eli Lilly and Company, AstraZeneca, Eisai Inc., TAIHO ONCOLOGY, INC., Bayer AG, Bristol-Myers Squibb Company., Incyte, Genentech USA, Inc., Exelixis, Inc., and Merck & Co., Inc.

📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=liver-cancer-treatment-market?rk

➣ Key Segments:

By Cancer Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Others.

By Treatment Type: Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Surgery, Ablation and Embolization Therapies, Others.

By Route of Administration: Injectable, Oral.

📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/liver-cancer-treatment-market?rk

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/liver-cancer-treatment-market?rk

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.